News >

Tagraxofusp Elicits Responses in Treatment-Naive and Relapsed BPDCN

Gina Columbus @ginacolumbusonc
Published: Thursday, Apr 25, 2019

Naveen Pemmaraju, MD

Naveen Pemmaraju, MD

Tagraxofusp (SL-401; Elzonris) led to a 90% overall response rate (ORR) as a first-line therapy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to prospective results of a nonrandomized phase II trial that were published in the New England Journal of Medicine.1

Tagraxofusp is also being investigated in clinical trials for chronic myelomonocytic leukemia and myelofibrosis.


  1. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Eng J Med. 2019;380:1628-1637. doi: 10.1056/NEJMoa1815105.
  2. Study of Tagraxofusp Reports 90 Percent Response Rate for Deadly Blood Cancer with no Prior Available Therapies. The University of Texas MD Anderson Cancer Center. Published April 25, 2019. Accessed April 25, 2019.
  3. Pemmaraju N, Lane AA, Sweet KL, et al. Results of pivotal phase 2 clinical trial of tagraxofusp (SL-401) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In: Proceedings from the 2018 ASH Annual Meeting; December 1-4, 2018; San Diego, California. Abstract 765.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication